EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Mon, 03.03.2025
THIS ANNOUNCEMENT, INCLUDING THE INFORMATION INCLUDED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF THE SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.
THIS ANNOUNCEMENT IS FOR INFOR...
Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024.
Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (pre...
Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023
The Management Board of Fresenius Management SE decided today that Fresenius Group will retain the governmental compensation and reimbursement payments of up to €300 million (from t...
Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius ex...
Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius ex...
As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“the Issuer”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“FMC”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft).
...
As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“the Issuer”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“FMC”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft).
...
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to...
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to...
Fresenius SE & Co. KGaA: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
Since Fresenius Medical Care continues to operate in a challenging environment, the impacts of the Company’s focused efforts to improve North American Health Care...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .